Acquisitions - Schedule of Assets Acquired and Liabilities Assumed (Details) - USD ($) $ in Millions |
Jul. 25, 2025 |
Dec. 27, 2023 |
Dec. 31, 2025 |
Dec. 31, 2024 |
|---|---|---|---|---|
| Business Combination [Line Items] | ||||
| Goodwill | $ 5,898 | $ 5,770 | ||
| Verve Therapeutics, Inc. | ||||
| Business Combination [Line Items] | ||||
| Cash | $ 389 | |||
| Acquired IPR&D | 608 | |||
| Goodwill | 127 | |||
| Other assets and liabilities, net | 39 | |||
| Acquisition date fair value of consideration transferred | 1,163 | |||
| Less: | ||||
| Cash acquired | (389) | |||
| Fair value of CVR liability | (177) | |||
| Fair value of equity interest in Verve held before the business combination | (48) | |||
| Cash paid, net of cash acquired | $ 549 | |||
| Point Biopharma Global Inc | ||||
| Business Combination [Line Items] | ||||
| Cash | $ 303 | |||
| Acquired IPR&D | 196 | |||
| Goodwill | 854 | |||
| Other assets and liabilities, net | (14) | |||
| Acquisition date fair value of consideration transferred | 1,339 | |||
| Less: | ||||
| Cash acquired | (303) | |||
| Cash paid, net of cash acquired | $ 1,036 |
| X | ||||||||||
- Definition Business Combination, Cash Acquired No definition available.
|
| X | ||||||||||
- Definition Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets (Liabilities), Net No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of cash and cash equivalent acquired in business combination and recognized at acquisition date. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of identifiable intangible asset acquired in business combination and recognized at acquisition date. Excludes goodwill and financial asset. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of asset acquired in excess of (less than) liability assumed plus goodwill in business combination and recognized at acquisition date. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Fair value at acquisition date of equity interest in acquiree held by acquirer immediately before acquisition date in business combination achieved in stages. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|